Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
Morgan Stanley began coverage on shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in a research report released on ...
If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
The Motley Fool on MSN13d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its HandsIn fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
Looking at options history for Novo Nordisk NVO we detected 8 trades. If we consider the specifics of each trade, it is ...
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback